Laser or shock waves: which eases stroke spasticity better?

NCT ID NCT07364110

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two non-invasive treatments—high-intensity laser therapy (HILT) and extracorporeal shock wave therapy (ESWT)—to reduce calf muscle stiffness and improve walking in 39 people who had a stroke at least three months earlier. Both therapies aim to relax spastic muscles without drugs or surgery. The researchers measured changes in muscle tone and ankle movement to see which treatment worked better.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

39 people

The number who actually took part.

Started

May 2021

Finished

Mar 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. First-ever stroke; 2. At least 3 months elapsed since stroke onset; 3. Age ≥18 years; 4. Presence of ankle plantar flexor spasticity graded 1-3 on the Modified Ashworth Scale (MAS); 5. Ability to ambulate independently or under supervision with or without assistive devices/orthoses; 6. Sufficient cognitive capacity to understand and follow test instructions Exclusion Criteria: * Fixed ankle contracture (peak ankle dorsiflexion \<0° with the knee in extension); * Current use of antispastic medications or a history of botulinum toxin injection within the previous 4 months; * Any orthopedic, rheumatologic, neurologic, cardiovascular, or visual comorbidity other than stroke that could affect gait; * Insufficient cognitive function.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Stroke gait rehabilitation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Equinus Deformity Muscle Spasticity stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Necmettin Erbakan University, Meram Medical School

    Konya, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.